ArticleMaterials today. Bio2023
Intra-articular treatment of temporomandibular joint osteoarthritis by injecting actively-loaded meloxicam liposomes with dual-functions of anti-inflammation and lubrication.
Article in Materials today. Bio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- Do successive intra-articular injections of tenoxicam or meloxicam affect the treatment outcomes of temporomandibular joint anterior disc displacement with reduction? (a randomized controlled trial).Oral and maxillofacial surgery · 2026Trial
- Trojan horse-inspired vaccine-like nanoparticle with enhanced lubrication and active-passive synergistic anti-inflammation for post-traumatic osteoarthritis treatment.Bioactive materials · 2027Article
- Sustained Intra-Articular Delivery of Triple Therapeutics Using a Phase-Transition Phospholipid-Based Gel for Effective Treatment of Gouty Arthritis.Pharmaceutical research · 2026Article
- Osteoarthritis: Epidemiology, Diagnosis, and Treatment.MedComm · 2026Review
- mMolecular medicine reports · 2026Review
- Nanozyme hydrogels remodel pathological microenvironment for temporomandibular joint osteoarthritis therapy via inhibiting MAPK signal pathway.Bioactive materials · 2026Article
- Advancement on localized targeting via intra-articular administration of lipid-based vesicular nanoparticles for osteoarthritis management.Journal of nanobiotechnology · 2026Review
- Smart Hydrogel for the Treatment of Rheumatoid Arthritis.Gels (Basel, Switzerland) · 2026Review
- Cationic hydrogel with sustained lubrication and anti-calcification for osteoarthritis therapy.Journal of nanobiotechnology · 2026Article
- Physicochemical Characterization and In Vitro Evaluation of Novel Liposomal and Proliposomal Doxorubicin Formulations in Accordance with FDA Guidance.AAPS PharmSciTech · 2026Article
- Engineered Nanomaterials for Drug Delivery in Temporomandibular Joint Osteoarthritis: Translational Insights and Current Advances.International journal of nanomedicine · 2026Review
- Liposome-Based Interventions in Knee Osteoarthritis.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Lubrication for Osteoarthritis: From Single-Function to Multifunctional Lubricants.International journal of molecular sciences · 2025Review
- Review
- Nanomaterials in the diagnosis and therapy of osteoarthritis: current research advances and future clinical prospects.Frontiers in bioengineering and biotechnology · 2025Review
- Lubricant Strategies in Osteoarthritis Treatment: Transitioning from Natural Lubricants to Drug Delivery Particles with Lubricant Properties.Journal of xenobiotics · 2024Review
- Non-Steroidal Anti-Inflammatory Drugs Administered Intra-Articularly in Temporomandibular Joint Disorders: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Hyaluronic Acid-Based Microparticles with Lubrication and Anti-Inflammation for Alleviating Temporomandibular Joint Osteoarthritis.Biomaterials research · 2024Article
- Functional Nanomaterials for the Treatment of Osteoarthritis.International journal of nanomedicine · 2024Review
- Advanced nanoparticles in osteoarthritis treatment.Biomaterials translational · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Temporomandibular joint (TMJ) osteoarthritis is a common osteochondral degenerative disease which can severely affect patient's mouth opening and mastication. Meloxicam (MLX), one of the most widely used non-steroidal anti-inflammatory drugs, is the main clinical therapy for the treatment of TMJ osteoarthritis. However, the clinical effect is greatly compromised because of its poor water solubility and high lipophilicity. In the present study, we developed an actively-loaded liposomal formulation, namely MLX-Ca(AC)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.